Thrombocytopenia - Pipeline Review, H2 2016

Global Markets Direct’s, ‘Thrombocytopenia - Pipeline Review, H2 2016’, provides an overview of the Thrombocytopenia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Thrombocytopenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thrombocytopenia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Thrombocytopenia

The report reviews pipeline therapeutics for Thrombocytopenia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Thrombocytopenia therapeutics and enlists all their major and minor projects

The report assesses Thrombocytopenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Thrombocytopenia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Thrombocytopenia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Thrombocytopenia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc.

AkaRx Inc

Amarillo Biosciences, Inc.

Amgen Inc.

arGEN-X BV

BioLineRx, Ltd.

Biotest AG

Boehringer Ingelheim GmbH

Bolder Biotechnology, Inc.

Bristol-Myers Squibb Company

Cellerant ...

3SBio Inc.

AkaRx Inc

Amarillo Biosciences, Inc.

Amgen Inc.

arGEN-X BV

BioLineRx, Ltd.

Biotest AG

Boehringer Ingelheim GmbH

Bolder Biotechnology, Inc.

Bristol-Myers Squibb Company

Cellerant Therapeutics, Inc.

Genosco

Hansa Medical AB

Immunomedics, Inc.

Intas Pharmaceuticals Ltd.

Jiangsu Hengrui Medicine Co., Ltd.

Merck & Co., Inc.

Momenta Pharmaceuticals, Inc.

Myelo Therapeutics GmbH

Neumedicines Inc.

Novartis AG

Pfizer Inc.

PhytoHealth Corporation

Prophylix Pharma AS

Protalex, Inc.

Rigel Pharmaceuticals, Inc.

Shionogi & Co., Ltd.

Shire Plc

STATegics, Inc.

UCB SA

ViroMed Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Thrombocytopenia Overview ...

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Thrombocytopenia Overview 8

Therapeutics Development 9

Pipeline Products for Thrombocytopenia - Overview 9

Pipeline Products for Thrombocytopenia - Comparative Analysis 10

Thrombocytopenia - Therapeutics under Development by Companies 11

Thrombocytopenia - Therapeutics under Investigation by Universities/Institutes 13

Thrombocytopenia - Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Thrombocytopenia - Products under Development by Companies 17

Thrombocytopenia - Products under Investigation by Universities/Institutes 20

Thrombocytopenia - Companies Involved in Therapeutics Development 21

3SBio Inc. 21

AkaRx Inc 22

Amarillo Biosciences, Inc. 23

Amgen Inc. 24

arGEN-X BV 25

BioLineRx, Ltd. 26

Biotest AG 27

Boehringer Ingelheim GmbH 28

Bolder Biotechnology, Inc. 29

Bristol-Myers Squibb Company 30

Cellerant Therapeutics, Inc. 31

Genosco 32

Hansa Medical AB 33

Immunomedics, Inc. 34

Intas Pharmaceuticals Ltd. 35

Jiangsu Hengrui Medicine Co., Ltd. 36

Merck & Co., Inc. 37

Momenta Pharmaceuticals, Inc. 38

Myelo Therapeutics GmbH 39

Neumedicines Inc. 40

Novartis AG 41

Pfizer Inc. 42

PhytoHealth Corporation 43

Prophylix Pharma AS 44

Protalex, Inc. 45

Rigel Pharmaceuticals, Inc. 46

Shionogi & Co., Ltd. 47

Shire Plc 48

STATegics, Inc. 49

UCB SA 50

ViroMed Co Ltd 51

Thrombocytopenia - Therapeutics Assessment 52

Assessment by Monotherapy Products 52

Assessment by Target 53

Assessment by Mechanism of Action 55

Assessment by Route of Administration 57

Assessment by Molecule Type 59

Drug Profiles 61

Antibody for Autoimmune Disorders and Inflammation - Drug Profile 61

ARGX-113 - Drug Profile 62

avatrombopag - Drug Profile 64

BBT-059 - Drug Profile 66

BI-655064 - Drug Profile 67

BL-8040 - Drug Profile 69

BMS-986004 - Drug Profile 80

BT-595 - Drug Profile 81

CLT-009 - Drug Profile 82

eltrombopag olamine - Drug Profile 83

eltrombopag olamine - Drug Profile 89

fostamatinib disodium - Drug Profile 90

GL-2045 - Drug Profile 96

GSK-2285921 - Drug Profile 97

Hetrombopag Olamine - Drug Profile 99

interferon alfa - Drug Profile 100

lusutrombopag - Drug Profile 102

M-281 - Drug Profile 103

MK-8723 - Drug Profile 104

Monoclonal Antibody to Agonize Thrombopoietin Receptor for Thrombocytopenia - Drug Profile 105

Monoclonal Antibody to Antagonize FcgR1 for Inflammatory and Autoimmune Disorders - Drug Profile 106

Monoclonal Antibody to Antagonize FcgRIIa for Inflammatory and Autoimmune Disorders - Drug Profile 107

Myelo-001 - Drug Profile 108

NMIL-121 - Drug Profile 109

Oligonucleotides to Activate miRNA-150 for Thrombocytopenia and Anemia - Drug Profile 112

PEG-VM501 - Drug Profile 113

PHN-013 - Drug Profile 114

PRTX-100 - Drug Profile 115

Recombinant Enzyme to Inhibit Immunoglobulin G for Autoimmune Diseases - Drug Profile 122

romiplostim - Drug Profile 123

romiplostim biosimilar - Drug Profile 126

SHP-652 - Drug Profile 127

SKIO-703 - Drug Profile 130

Small Molecules to Inhibit BLVRB for Thrombocytopenia - Drug Profile 131

Small Molecules to Inhibit PF4 for Heparin Induced Thrombocytopenia - Drug Profile 132

STST-4 - Drug Profile 133

thrombopoietin - Drug Profile 134

Tromplate - Drug Profile 135

TXA-302 - Drug Profile 136

UCB-7665 - Drug Profile 137

veltuzumab - Drug Profile 138

Thrombocytopenia - Dormant Projects 142

Thrombocytopenia - Discontinued Products 145

Thrombocytopenia - Product Development Milestones 146

Featured News & Press Releases 146

Appendix 159

Methodology 159

Coverage 159

Secondary Research 159

Primary Research 159

Expert Panel Validation 159

Contact Us 159

Disclaimer 160

List of Tables

List of Tables

Number of Products under Development for Thrombocytopenia, H2 2016 12

Number of Products under Development for Thrombocytopenia - Comparative Analysis, H2 2016 ...

List of Tables

Number of Products under Development for Thrombocytopenia, H2 2016 12

Number of Products under Development for Thrombocytopenia - Comparative Analysis, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Number of Products under Development by Companies, H2 2016 (Contd..1) 15

Number of Products under Investigation by Universities/Institutes, H2 2016 16

Comparative Analysis by Late Stage Development, H2 2016 17

Comparative Analysis by Clinical Stage Development, H2 2016 18

Comparative Analysis by Early Stage Development, H2 2016 19

Products under Development by Companies, H2 2016 20

Products under Development by Companies, H2 2016 (Contd..1) 21

Products under Development by Companies, H2 2016 (Contd..2) 22

Products under Investigation by Universities/Institutes, H2 2016 23

Thrombocytopenia - Pipeline by 3SBio Inc., H2 2016 24

Thrombocytopenia - Pipeline by AkaRx Inc, H2 2016 25

Thrombocytopenia - Pipeline by Amarillo Biosciences, Inc., H2 2016 26

Thrombocytopenia - Pipeline by Amgen Inc., H2 2016 27

Thrombocytopenia - Pipeline by arGEN-X BV, H2 2016 28

Thrombocytopenia - Pipeline by BioLineRx, Ltd., H2 2016 29

Thrombocytopenia - Pipeline by Biotest AG, H2 2016 30

Thrombocytopenia - Pipeline by Boehringer Ingelheim GmbH, H2 2016 31

Thrombocytopenia - Pipeline by Bolder Biotechnology, Inc., H2 2016 32

Thrombocytopenia - Pipeline by Bristol-Myers Squibb Company, H2 2016 33

Thrombocytopenia - Pipeline by Cellerant Therapeutics, Inc., H2 2016 34

Thrombocytopenia - Pipeline by Genosco, H2 2016 35

Thrombocytopenia - Pipeline by Hansa Medical AB, H2 2016 36

Thrombocytopenia - Pipeline by Immunomedics, Inc., H2 2016 37

Thrombocytopenia - Pipeline by Intas Pharmaceuticals Ltd., H2 2016 38

Thrombocytopenia - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 39

Thrombocytopenia - Pipeline by Merck & Co., Inc., H2 2016 40

Thrombocytopenia - Pipeline by Momenta Pharmaceuticals, Inc., H2 2016 41

Thrombocytopenia - Pipeline by Myelo Therapeutics GmbH, H2 2016 42

Thrombocytopenia - Pipeline by Neumedicines Inc., H2 2016 43

Thrombocytopenia - Pipeline by Novartis AG, H2 2016 44

Thrombocytopenia - Pipeline by Pfizer Inc., H2 2016 45

Thrombocytopenia - Pipeline by PhytoHealth Corporation, H2 2016 46

Thrombocytopenia - Pipeline by Prophylix Pharma AS, H2 2016 47

Thrombocytopenia - Pipeline by Protalex, Inc., H2 2016 48

Thrombocytopenia - Pipeline by Rigel Pharmaceuticals, Inc., H2 2016 49

Thrombocytopenia - Pipeline by Shionogi & Co., Ltd., H2 2016 50

Thrombocytopenia - Pipeline by Shire Plc, H2 2016 51

Thrombocytopenia - Pipeline by STATegics, Inc., H2 2016 52

Thrombocytopenia - Pipeline by UCB SA, H2 2016 53

Thrombocytopenia - Pipeline by ViroMed Co Ltd, H2 2016 54

Assessment by Monotherapy Products, H2 2016 55

Number of Products by Stage and Target, H2 2016 57

Number of Products by Stage and Mechanism of Action, H2 2016 59

Number of Products by Stage and Route of Administration, H2 2016 61

Number of Products by Stage and Molecule Type, H2 2016 63

Thrombocytopenia - Dormant Projects, H2 2016 145

Thrombocytopenia - Dormant Projects (Contd..1), H2 2016 146

Thrombocytopenia - Dormant Projects (Contd..2), H2 2016 147

Thrombocytopenia - Discontinued Products, H2 2016 148

List of Figures

List of Figures

Number of Products under Development for Thrombocytopenia, H2 2016 12

Number of Products under Development for Thrombocytopenia - Comparative Analysis, H2 2016 ...

List of Figures

Number of Products under Development for Thrombocytopenia, H2 2016 12

Number of Products under Development for Thrombocytopenia - Comparative Analysis, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Comparative Analysis by Late Stage Development, H2 2016 17

Comparative Analysis by Clinical Stage Development, H2 2016 18

Comparative Analysis by Early Stage Products, H2 2016 19

Assessment by Monotherapy Products, H2 2016 55

Number of Products by Top 10 Targets, H2 2016 56

Number of Products by Stage and Top 10 Targets, H2 2016 56

Number of Products by Top 10 Mechanism of Actions, H2 2016 58

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 58

Number of Products by Routes of Administration, H2 2016 60

Number of Products by Stage and Routes of Administration, H2 2016 60

Number of Products by Top 10 Molecule Types, H2 2016 62

Number of Products by Stage and Top 10 Molecule Types, H2 2016 62

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports